196 related articles for article (PubMed ID: 17521951)
21. Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7).
Durkin ME; Yuan BZ; Thorgeirsson SS; Popescu NC
Gene; 2002 Apr; 288(1-2):119-27. PubMed ID: 12034501
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.
Qian X; Li G; Asmussen HK; Asnaghi L; Vass WC; Braverman R; Yamada KM; Popescu NC; Papageorge AG; Lowy DR
Proc Natl Acad Sci U S A; 2007 May; 104(21):9012-7. PubMed ID: 17517630
[TBL] [Abstract][Full Text] [Related]
23. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ
Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950
[TBL] [Abstract][Full Text] [Related]
24. Focal adhesion-localization of START-GAP1/DLC1 is essential for cell motility and morphology.
Kawai K; Iwamae Y; Yamaga M; Kiyota M; Ishii H; Hirata H; Homma Y; Yagisawa H
Genes Cells; 2009 Feb; 14(2):227-41. PubMed ID: 19170769
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of DLC-1 gene expression by RNA interference in the colon cancer LoVo cell line.
Jin Y; Tian X; Shang Y; Huang P
Oncol Rep; 2008 Mar; 19(3):669-74. PubMed ID: 18288400
[TBL] [Abstract][Full Text] [Related]
26. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
Durkin ME; Avner MR; Huh CG; Yuan BZ; Thorgeirsson SS; Popescu NC
FEBS Lett; 2005 Feb; 579(5):1191-6. PubMed ID: 15710412
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
28. Tensins are versatile regulators of Rho GTPase signalling and cell adhesion.
Blangy A
Biol Cell; 2017 Mar; 109(3):115-126. PubMed ID: 27748980
[TBL] [Abstract][Full Text] [Related]
29. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.
Kim TY; Healy KD; Der CJ; Sciaky N; Bang YJ; Juliano RL
J Biol Chem; 2008 Nov; 283(47):32762-70. PubMed ID: 18786931
[TBL] [Abstract][Full Text] [Related]
30. DLC-1:a Rho GTPase-activating protein and tumour suppressor.
Durkin ME; Yuan BZ; Zhou X; Zimonjic DB; Lowy DR; Thorgeirsson SS; Popescu NC
J Cell Mol Med; 2007; 11(5):1185-207. PubMed ID: 17979893
[TBL] [Abstract][Full Text] [Related]
31. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma.
Wolosz D; Walczak A; Szparecki G; Dwojak M; Winiarska M; Wolinska E; Gornicka B
Eur J Histochem; 2019 Feb; 63(1):. PubMed ID: 30827083
[TBL] [Abstract][Full Text] [Related]
32. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain.
Ng DC; Chan SF; Kok KH; Yam JW; Ching YP; Ng IO; Jin DY
FEBS Lett; 2006 Jan; 580(1):191-8. PubMed ID: 16364308
[TBL] [Abstract][Full Text] [Related]
34. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.
Goodison S; Yuan J; Sloan D; Kim R; Li C; Popescu NC; Urquidi V
Cancer Res; 2005 Jul; 65(14):6042-53. PubMed ID: 16024604
[TBL] [Abstract][Full Text] [Related]
35. DLC1 is the principal biologically-relevant down-regulated DLC family member in several cancers.
Wang D; Qian X; Rajaram M; Durkin ME; Lowy DR
Oncotarget; 2016 Jul; 7(29):45144-45157. PubMed ID: 27174913
[TBL] [Abstract][Full Text] [Related]
36. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
Ko FC; Yeung YS; Wong CM; Chan LK; Poon RT; Ng IO; Yam JW
Liver Int; 2010 Jan; 30(1):139-48. PubMed ID: 19874489
[TBL] [Abstract][Full Text] [Related]
37. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
[TBL] [Abstract][Full Text] [Related]
38. Individual domains of Tensin2 exhibit distinct subcellular localisations and migratory effects.
Hafizi S; Sernstad E; Swinny JD; Gomez MF; Dahlbäck B
Int J Biochem Cell Biol; 2010 Jan; 42(1):52-61. PubMed ID: 19747564
[TBL] [Abstract][Full Text] [Related]
39. Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.
Hall EH; Daugherty AE; Choi CK; Horwitz AF; Brautigan DL
J Biol Chem; 2009 Dec; 284(50):34713-22. PubMed ID: 19826001
[TBL] [Abstract][Full Text] [Related]
40. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
Ko FC; Chan LK; Tung EK; Lowe SW; Ng IO; Yam JW
Gastroenterology; 2010 Oct; 139(4):1397-407. PubMed ID: 20600027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
